These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35631444)

  • 1. Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity.
    Huntington KE; Carlsen L; So EY; Piesche M; Liang O; El-Deiry WS
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity.
    Huntington KE; Carlsen L; So EY; Piesche M; Liang O; El-Deiry WS
    medRxiv; 2022 Jan; ():. PubMed ID: 35018385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
    Zhou L; Huntington K; Zhang S; Carlsen L; So EY; Parker C; Sahin I; Safran H; Kamle S; Lee CM; Lee CG; Elias JA; Campbell KS; Naik MT; Atwood WJ; Youssef E; Pachter JA; Navaraj A; Seyhan AA; Liang O; El-Deiry WS
    bioRxiv; 2020 Sep; ():. PubMed ID: 32793908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.
    Hejenkowska ED; Mitash N; Donovan JE; Chandra A; Bertrand C; De Santi C; Greene CM; Mu F; Swiatecka-Urban A
    J Innate Immun; 2023; 15(1):629-646. PubMed ID: 37579743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection.
    Zhou L; Huntington K; Zhang S; Carlsen L; So EY; Parker C; Sahin I; Safran H; Kamle S; Lee CM; Geun Lee C; A Elias J; S Campbell K; T Naik M; J Atwood W; Youssef E; A Pachter J; Navaraj A; A Seyhan A; Liang O; El-Deiry WS
    Oncotarget; 2020 Nov; 11(46):4201-4223. PubMed ID: 33245731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
    Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
    Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
    Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
    J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.
    Ma C; Chen X; Mei F; Xiong Q; Liu Q; Dong L; Liu C; Zou W; Zhan F; Hu B; Liu Y; Liu F; Zhou L; Xu J; Jiang Y; Xu K; Cai K; Chen Y; Yan H; Lan K
    Emerg Microbes Infect; 2022 Dec; 11(1):567-572. PubMed ID: 35060426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
    Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
    Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern.
    Yang H; Liu P; Zhang Y; Du T; Zhou Y; Lu S; Peng X
    MedComm (2020); 2022 Jun; 3(2):e129. PubMed ID: 35434714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation.
    Li Z; Yong H; Wang W; Gao Y; Wang P; Chen X; Lu J; Zheng J; Bai J
    J Med Virol; 2023 Jan; 95(1):e28158. PubMed ID: 36114164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.
    Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH
    Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection.
    Beeg M; Baroni S; Piotti A; Porta A; De Luigi A; Cagnotto A; Gobbi M; Diomede L; Salmona M
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.